Dechra Pharmaceuticals PLC

Dechra Pharmaceuticals PLC

Annual Report and Accounts for the year ended 30 June 2012

(iv) Intangible Assets

Acquired Intangibles
£'000
Cost
At 1 July 2011
Additions5,114
At 30 June 20125,114
Amortisation
At 1 July 2011
Charge for the year213
At 30 June 2012213
Net book value
At 30 June 20124,901
At 30 June 2011

On 31 January 2012 the Company acquired the worldwide rights (excluding Canada) to HY-50, an equine lameness product. The total consideration was 8.0 million Canadian Dollars (£5.1 million) which was paid in cash on completion.

We use cookies and track users anonymously, check this box and save to disable. We are inferring consent by continuing.